Literature DB >> 34106888

Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.

Ali Toloue Ostadgavahi1, Ryan Booth1, Gary Sisson1, Nichole McMullen1, Michelle Warhuus2, Peter Robertson2, Matthew Miller2, Wanda C Allen2, May El Sherif2, Robert Brownlie3, Darryl Falzarano3, Christopher D Richardson4.   

Abstract

Understanding the efficacy and durability of heterologous immunization schedules against SARS-CoV-2 is critical, as supply demands and vaccine choices become significant issues in the global vaccination strategy. Here we characterize the neutralizing antibodies produced in two subjects who received combination immunizations against SARS-CoV-2, first with Covishield (Oxford-AstraZeneca) vaccine, followed 33 days later with a second dose (booster) shot of the Pfizer-BioNTech vaccine. Serum samples were collected 25 days following the primary vaccination and 13 days after the secondary Pfizer vaccination. Both subjects exhibited increased levels of isotype IgG and IgM antibodies directed against the entire spike protein following immunizations. These antibodies also exhibited increased reactivity with the receptor binding domain (RBD) in the spike protein and neutralized the infectivity of replicating vesicular stomatitis virus (VSV) that contains the COVID-19 coronavirus S protein gene in place of its normal G glycoprotein. This VSV pseudovirus also contains the reporter gene for enhanced green fluorescent protein (eGFP). Antibody titers against the spike protein and serum neutralization titers against the reporter virus are reported for the 2 heterologous vaccinated individuals and compared to a positive control derived from a convalescent patient and a negative control from an unexposed individual. The Pfizer-BioNTech vaccine increased antibody binding to the spike protein and RBD, and approached levels found in the convalescent positive control. Neutralizing antibodies against the VSV-S pseudovirus in the 2 subjects also approached levels in the convalescent sera. These results firmly validate the value of the Pfizer-BioNTech vaccine in boosting immunity following initial Covishield inoculation. Copyright (c) 2021 Ali Toloue Ostadgavahi, Ryan Booth, Gary Sisson, Nichole McMullen, Michelle Warhuus, Peter Robertson, Matthew Miller, Wanda C Allen, May El Sherif, Robert Brownlie, Darryl Falzarano, Christopher D Richardson.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; VSV-S reporter pseudovirus; heterologous immunization; humoral immunity; neutralizing antibodies; serum titers; vaccines

Mesh:

Substances:

Year:  2021        PMID: 34106888     DOI: 10.3855/jidc.15368

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  3 in total

1.  Heterologous ChAdOx1-nCoV19-BNT162b2 vaccination provides superior immunogenicity against COVID-19.

Authors:  Christopher D Richardson
Journal:  Lancet Respir Med       Date:  2021-08-13       Impact factor: 30.700

Review 2.  A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues.

Authors:  Shahad Saif Khandker; Brian Godman; Md Irfan Jawad; Bushra Ayat Meghla; Taslima Akter Tisha; Mohib Ullah Khondoker; Md Ahsanul Haq; Jaykaran Charan; Ali Azam Talukder; Nafisa Azmuda; Shahana Sharmin; Mohd Raeed Jamiruddin; Mainul Haque; Nihad Adnan
Journal:  Vaccines (Basel)       Date:  2021-11-24

Review 3.  Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.

Authors:  Thuy Trang Nguyen; Trang Ho Thu Quach; Thanh Mai Tran; Huynh Ngoc Phuoc; Ha Thi Nguyen; Tuong Kha Vo; Giau Van Vo
Journal:  Biomed Pharmacother       Date:  2022-01-19       Impact factor: 6.529

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.